Table 1.
Characteristics of study population.
| Number | 287 |
| Females | 86 (29.9%) |
| Males | 201 (70.1%) |
| Mean age ± SD (years) | 64.1 ± 12.6 |
| Mean LOS ± SD (days) | 19.5 ± 11.9 |
| Number of days since symptoms onset before hospital admission (mean ± SD, days) | 6.4 ± 4.2 |
| Mean P/F at hospital admission | 250.6 ± 81.2 |
| Respiratory support by NIV, CPAP-helmets and/or HFNC | 229 (80.5%) |
| Mean P/F at the day of Tocilizumab administration | 139.1 ± 52.9 |
| In-hospital mortality | 54 (18.8%) |
| ICU admission | 69 (24.0%) |
| Without OTI | 36 (12.5%) |
| With OTI | 33(11.5%) |
| In-hospital mortality and/or ICU admission with OTI | 68 (23.7%) |
| In-hospital mortality in patients admitted in ICU | 29 (42.0%) |
Legend: LOS=lenght of hospital stay; P/F= paO2/FiO2 ratio; HFNC=high flow nasal cannula; ICU=Intensive Care Unit; OTI=oro-tracheal intubation; NIV=non invasive ventilation.